Allogene Therapeutics Inc

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Allogene Therapeutics reports strong Q4 performance and financial stability

Allogene Therapeutics showcased promising clinical data for its AlloCAR T therapy and emphasized a strong financial position. While facing challenges in manufacturing optimization, the company is focused on pivotal trials and cost management. Opportunities for growth include product reintroductions and ongoing program updates.

Allogene reports positive Q1 results, eyes partnerships for growth

Allogene Therapeutics showcased positive patient responses and financial prudence in Q1 2023, underlining its commitment to innovation and efficiency.
While facing resource limitations and challenges in product development, the company is exploring partnerships and expansion opportunities for future growth.
Overall, Allogene's strategic focus on patient care, operational excellence, and therapeutic advancements positions it well for continued success in the biopharmaceutical industry.

Allogene Therapeutics reports Q2 losses but showcases promising CAR-T results

Allogene Therapeutics' Q2 2023 performance reflects strategic investments in R&D and operational expenses, supported by a strong balance sheet and promising results in their allogeneic CAR-T program.
While facing challenges in patient access, manufacturing, and collaborations, the company is well-positioned to capitalize on opportunities in global expansion, next-gen technologies, and clinical trial progress.
With a focus on innovation, operational efficiency, and market expansion, Allogene Therapeutics navigates complexities in the CAR-T space to drive growth and advance its therapeutic offerings.

Allogene Therapeutics excels in Q3, poised for CAR T leadership

Allogene Therapeutics showcased strong financials, promising clinical trial results, and strategic leadership changes.
The focus on allogeneic CAR T therapy positions the company for growth and market leadership.
Challenges include competition, regulatory complexities, and ensuring manufacturing scalability.
Opportunities lie in expanding trials, presenting at key conferences, and advancing pipeline innovations.

Allogene Therapeutics reports robust financials and advances innovative therapies

Allogene Therapeutics showcased strong financials, innovative trials, and strategic partnerships, positioning the company for future growth and therapeutic advancements.
While facing challenges from external factors and clinical complexities, Allogene has opportunities to expand its therapeutic reach and enhance treatment efficacy.
Investor interest in Allogene's pipeline and the company's positive response to inquiries reflect a promising outlook for continued development and success.
Allogene's focus on cutting-edge therapies, financial stability, and community engagement underscore its commitment to advancing patient care and addressing unmet medical needs.

Allogene Therapeutics reports strong Q1 performance and eyes autoimmune expansion

Allogene Therapeutics demonstrated solid financial performance in Q1 2024, with strategic investments and a focus on core programs.
Challenges in enrollment processes, dosing strategies, and safety considerations underscore the complexities of therapeutic development.
Opportunities lie in expanding into autoimmune indications, leveraging unique treatment approaches, and impacting the CAR T treatment landscape.

Allogene Therapeutics reports Q2 momentum, faces challenges, eyes growth

Allogene Therapeutics demonstrated positive momentum and strategic planning in Q2 2024, focusing on key programs and collaborations.
While financial challenges exist, the company's strengths in manufacturing capabilities and program advancements provide a solid foundation.
Addressing challenges like differentiation in the autoimmune space and financial losses will be crucial for sustained growth.
Opportunities for growth are present in continued program progress, FDA collaborations, and strategic milestones like IND filings.

Allogene Therapeutics advances in CAR-T therapies amidst financial challenges

Allogene Therapeutics showcased promising advancements in Q3 2024 across multiple therapeutic areas, positioning itself as a key player in the CAR-T therapy space.
While financial challenges persist, the company's strong cash position and strategic focus on transformative therapies provide a solid foundation for future growth.
Addressing concerns raised by analysts regarding data, safety, and trial participation will be crucial for maintaining investor confidence and advancing clinical development.
Overall, Allogene's dedication to pioneering treatments in oncology and autoimmune diseases underscores its potential for long-term success and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024 at 6:10 a.m. PT/9:10 a.m. ET.

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will restate previously issued financial statements for the years ended December 31, 2020, 2021 and 2022 and interim quarters during 2022 and 2023 due to non-cash accounting adjustments associated with the December 2020 formation of the Allogene Overland Biopharm joint venture in Asia.

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

Allogene (ALLO) decides to deprioritize two pivotal studies for the third-line treatment of certain lymphoma patients and start a new study to focus on the first-line treatment of the indication.

Allogene (ALLO) Down 20% on Strategic Changes in Pipeline

Biotechnology company Allogene (NASDAQ: ALLO ) is certainly not having the day that many in the company's C-Suite may have anticipated. Shares of ALLO stock are plunging yet again, dropping more than 15% on two key announcements.

Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts

Allogene Therapeutics Inc (NASDAQ:ALLO) shares tumbled at the open Friday after the company revealed plans to cut 22% of its workforce, part of a strategic shift in pipeline prioritization and clinical development strategy. The company anticipates completing the workforce reduction by the end of January 2024, with estimated charges of approximately $5 million to $5.5 million for severance payments and employee benefits, primarily in the first quarter of 2024.

Allogene Therapeutics to lay off over 20% of workforce amidst strategic shift

Allogene Therapeutics said on Friday it will cut 22% of its workforce as part of a clinical development strategy aimed at prioritizing its product pipeline.

Allogene to cut 22% of its workforce

SAN FRANCISCO and BOULDER, Colo., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection today announced a strategic partnership to develop a minimal residual disease (MRD) in-vitro diagnostic (IVD) to determine eligibility in ALPHA3, the first pivotal trial for first line (1L) consolidation treatment of large B-cell lymphoma (LBCL).

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced its 2024 Platform Vision that redefines the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will host a conference call to preview its 2024 Platform Vision focused on redefining the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

BeiGene

Bristol-Myers

Eli Lilly

Tango Therapeutics

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the presentation of data from a comprehensive safety review of patients treated in the Phase 1 ALPHA/ALPHA2 trials with ALLO-501/501A at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in December.

Allogene Therapeutics Announces Participation in December Investor Conference

BioXcel Therapeutics

Torrid Holdings

JOANN

ProKidney

Sirius XM Holdings Inc

NuScale Power Corp

There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.

7 Penny Stocks With Low Floats and High Short Interest

Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should Know

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented data highlighting the Company's next generation Cloak™ and Dagger™ technologies designed to help enhance engraftment, expansion and the persistence of AlloCAR T cell candidates, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented preclinical data on a novel off-the-shelf AlloCAR T product candidate targeting Claudin18.2 (CLDN18.2)-positive gastric and pancreatic tumors, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.

Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Christine Cassiano – Chief Corporate Affairs and Brand Strategy Officer David Chang – President and Chief Executive Officer Zachary Roberts – Executive Vice President of Research and Development and Chief Medical Officer Geoff Parker – Chief Financial Officer Conference Call Participants Michael Yee – Jefferies Tyler Van Baron – TD Cowen Brian Cheng – JPMorgan Jack Allen – Baird Kelsey Goodwin – Guggenheim Securities John Newman – Canaccord Genuity Andy Fleszar – B. Riley Sami Corwin – William Blair Hartaj Singh – Oppenheimer Operator Hello, and thank you for standing by.

Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2023.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in November.

Allogene Therapeutics Announces Participation in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report third quarter 2023 financial results on Thursday, November 2, 2023, after the close of the market.

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

Eos Energy Enterprises

In the investing world, there's a popular strategy that often captivates the attention of traders and investors alike – monitoring stocks with a significant short interest.

Short squeeze alert for October 10th: 2 stocks with potential to explode

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA. These presentations will focus on the Company's next generation AlloCAR T platform technologies and the foundation for an early-stage solid tumor product candidate, ALLO-182.

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Stocks that are heavily shorted have the potential to skyrocket as traders are forced to cover their short positions by buying back the stock. This can be an extremely profitable strategy if you find the right stock at the right time.

News for Allogene Therapeutics Inc Stock (ALLO)